Submissions from 2024
Patient Time Spent With Professional Medical Interpreters and the Care Experiences of Patients With Limited English Proficiency., Pamela Torresdey, Jacob Chen, and Hector P Rodriguez
Rationale and design of the Nephrotic Syndrome Study Network (NEPTUNE) Match in glomerular diseases: designing the right trial for the right patient, today., Howard Trachtman, Hailey Desmond, Amanda L Williams, Laura H Mariani, Sean Eddy, Wenjun Ju, Laura Barisoni, Heather K Ascani, Wendy R Uhlmann, Cathie Spino, Lawrence B Holzman, John R Sedor, Crystal Gadegbeku, Lalita Subramanian, Chrysta C Lienczewski, Tina Manieri, Scott J Roberts, Debbie S Gipson, Matthias Kretzler, NEPTUNE investigators, and Katherine Tuttle (NEPTUNE investigators)
Adoptive cell therapy targeting mutations in gastrointestinal cancers, Eric Tran
Cell transfer therapy targeting oncogenic mutations, Eric Tran
More T cell receptors to the RAScue in cancer?, Eric Tran
Past, Present, and Future of Cellular Immunotherapy, Eric Tran
Erratum to “Sammie Mosier, DHA, MA, BSN, NE-BC” [Nurse Leader 22/5 (2024) 491-495], Sylvain Trepanier
Leader To Watch: Sammie Mosier, DHA, MA, BSN, NE-BC, Sylvain Trepanier
Safe Staffing Through New Models of Care, Sylvain Trepanier, Kathleen Sanford, Gay Landstrom, Rosalie Mainous, and Susan Bakewell-Sachs
Safe Staffing Through New Models of Care, Sylvain Trepanier, Kathleen Sanford, Gay Landstrom, Rosalie Mainous, and Susan Bakewell-Sachs
Second Malignant Neoplasms Following Treatment for Hepatoblastoma: An International Report and Review of the Literature., Angela Trobaugh-Lotrario, Kenichiro Watanabe, Allison F O'Neill, Bozenna Dembowska-Bagińska, Beate Häberle, Andrew Murphy, Eiso Hiyama, Piotr Czauderna, Rebecka L Meyers, Max Langham, and James Feusner
Imaging in vasculitis., Orrin M Troum, Olga L Pimienta, and Alvin Wells
Journal names its 25 People of Influence in 2025, Katherine Tuttle (author mention)
379. SGLT Inhibitors: The Biology of SGLT Inhibition with Dr. Katherine Tuttle, Katherine Tuttle
“Adjunctive Therapy in T1D”, Katherine Tuttle
“A Pinch of Salt – A Podcast by ERA”, Katherine Tuttle
“Benefits of Semaglutide on Chronic Kidney Disease Outcomes by Cardiovascular Status of Risk in the FLOW Trial.", Katherine Tuttle
“Benefits of semaglutide on chronic kidney disease outcomes by cardiovascular status or risk in the FLOW trial.", Katherine Tuttle
“Building your academic career portfolio”, Katherine Tuttle
“Cardiovascular-Kidney-Metabolic Syndrome, Katherine Tuttle
“Cases in Diabetes, Kidney, and Cardio-Renal-Metabolic Disease”, Katherine Tuttle
CKD screening for better kidney health: Why? Who? How? When?, Katherine Tuttle
Clinical and Mechanistic Effects of GLP-1 Receptor Agonists in CKD, Katherine Tuttle
“Diabetic Nephropathy 2024: Comprehensive Care for People with Diabetes Mellitus and Advanced Chronic Kidney Disease.", Katherine Tuttle
“DM and CKD Treatments: Which Treatment Should I Use for Different Populations?”, Katherine Tuttle
“Effects of Semaglutide on CKD in Patients with Type 2 Diabetes (FLOW)”, Katherine Tuttle
“Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial.”, Katherine Tuttle
“FLOW: A new treatment paradigm for people with T2D and chronic kidney disease”, Katherine Tuttle
“FLOW: Benefits of Semaglutide on CKD by Cardiovascular Status or Risk.”, Katherine Tuttle
“FLOW Result: Summary and Clinical Implication, Katherine Tuttle
“FLOW: Semaglutide scores big in diabetic patients with CKD”, Katherine Tuttle
“ GLP1-RA in CKD”, Katherine Tuttle
GLP-1 Receptor Agonists for CKD in Diabetes and Beyond…, Katherine Tuttle
“GLP-1 Receptor Agonists for CKD in Diabetics and Beyond”, Katherine Tuttle
“Glycemic Management in Persons with Diabetes and CKD”, Katherine Tuttle
“Going with the FLOW: Understanding the renal effects of GLP-1RA Therapy”, Katherine Tuttle
Helio “Aldosterone inhibitor BI 690517 reduced albuminuria when combined with SGLT2 inhibitor”, Katherine Tuttle
Horizons-EASD eLearning, Katherine Tuttle
“How GLP1 receptor agonist evolved from weight management drug to kidney protective therapy”, Katherine Tuttle
“How Will the Incretin Data “FLOW” into Practice?”, Katherine Tuttle
“ Key considerations for tailoring treatment approaches for diabetic patients with chronic kidney disease", Katherine Tuttle
“Kidney Compass Podcast with Drs. Neuen/Wadhwani & Tuttle, Katherine Tuttle
“Kidney Disease and Obesity”, Katherine Tuttle
“Kidney Health for All: Advancing equitable access to care and optimal medication practice”, Katherine Tuttle
“Kidney Week 2024 Press Conference”, Katherine Tuttle
“Kidney Week 2024 Video Interview”, Katherine Tuttle
“Landmark studies”, Katherine Tuttle
“Miracle weight-loss drugs could halt kidney disease too”, Katherine Tuttle
"National Academies Workshop – Preparing the Future Workforce in Drug andResearch Development", Katherine Tuttle
National Geographic Interview feature article, Katherine Tuttle
“Navigating the Sea Change of CKD Treatment in Diabetes”, Katherine Tuttle
“Nephrology Times Interview”, Katherine Tuttle
“New study shows Ozempic lowers kidney disease”, Katherine Tuttle
“New use for Ozempic”, Katherine Tuttle
“Ozempic cuts risk in kidney disease”, Katherine Tuttle
“Ozempic cuts risk of chronic kidney disease complications, study finds””, Katherine Tuttle
“Ozempic keeps wowing: trial data show benefits for kidney disease”, Katherine Tuttle
“Ozempic reduces risk of serious illness and death in people with diabetes and kidney disease, study finds", Katherine Tuttle
Plenary - “Kidney Health and CKD Prevention Herald a Sea Change in Nephrology”, Katherine Tuttle
Research Development., Katherine Tuttle
“Sea Change in CKD”, Katherine Tuttle
“Semaglutide cuts kidney failure and death in diabetes”, Katherine Tuttle
“Semaglutide Reduced Risks of Major Kidney Outcomes Irrespective of CKD Severity in the FLOW Trial”, Katherine Tuttle
“Semaglutide significantly improves chronic kidney disease”, Katherine Tuttle
“State-of-are Treatment for DKD”, Katherine Tuttle
“State of the art treatment for CKD”, Katherine Tuttle
“Study crystallizes distinct kidney benefits of common drug”, Katherine Tuttle
“Success of GLP-1 receptor agonists in kidney disease halts FLOW trial early.”, Katherine Tuttle
Talk with a Doc Podcast, Katherine Tuttle
The FLOW Trial of Semaglutide for CKD in Type 2 Diabetes: Kidney, Cardiovascular, and Mortality Outcomes, Katherine Tuttle
“The Next Stage: CKM Syndrome Progression and Implications for CVD Outcomes”, Katherine Tuttle
“Therapeutic Transformation of Chronic Kidney Disease”, Katherine Tuttle
“Therapeutic Transformation of Kidney Care – Diabetes and Beyond”, Katherine Tuttle
“Transformation of CKD Care to Delivery Kidney Health”, Katherine Tuttle
“Transforming CKD Care from Evidence Generation to Implementation”, Katherine Tuttle
Transforming CKD Care from Evidence Generation to Implementation, Katherine Tuttle
“Transforming Kidney Care – Breakthrough Therapies”, Katherine Tuttle
“Transforming Kidney Care by Equitable Implementation of Breakthrough Therapies”, Katherine Tuttle
Treatment of Chronic Kidney Disease and Heart Failure Circa 2024, Katherine Tuttle
“Why diabetes miracle drugs like Ozempic are off-limits to Type 1s”, Katherine Tuttle
Clinical Characteristics and Histopathology in Adults With Focal Segmental Glomerulosclerosis., Katherine Tuttle, Clint W Abner, Patrick D Walker, Kaijun Wang, Andrew Rava, Jihaeng Heo, and Martin Bunke
Clinical Characteristics and Histopathology in Adults With Focal Segmental Glomerulosclerosis., Katherine Tuttle, Clint W Abner, Patrick D Walker, Kaijun Wang, Andrew Rava, Jihaeng Heo, and Martin Bunke
Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial., Katherine Tuttle, Sibylle J Hauske, Maria Eugenia Canziani, Maria Luiza Caramori, David Cherney, Lisa Cronin, Hiddo J L Heerspink, Christian Hugo, Masaomi Nangaku, Ricardo Correa Rotter, Arnold Silva, Shimoli V Shah, Zhichao Sun, Dorothea Urbach, Dick de Zeeuw, and Peter Rossing
Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial., Katherine R Tuttle, Sibylle J Hauske, Maria Eugenia Canziani, Maria Luiza Caramori, David Cherney, Lisa Cronin, Hiddo J L Heerspink, Christian Hugo, Masaomi Nangaku, Ricardo Correa Rotter, Arnold Silva, Shimoli V Shah, Zhichao Sun, Dorothea Urbach, Dick de Zeeuw, Peter Rossing, and ASi in CKD group
Geometric Analysis Of Aortic Remodeling After PETTICOAT Technique In Type B Aortic Dissection, Brant Ullery
Adoption and clinical outcomes of fenestrated endovascular aneurysm repair in a regional, multistate community hospital system., Brant Ullery, Douglas Hanes, Eric B Kirker, and Kateri Spinelli
Anal Condyloma and Human Papillomavirus: Recognition, Treatment, and Prevention., Kenley R Unruh and Debra D Lai
Left atrial to coronary sinus shunting for treatment of heart failure with mildly reduced or preserved ejection fraction: The ALT FLOW Early Feasibility Study 1-year results., Marcus A Urey, Benjamin Hibbert, Ulrich Jorde, Peter Eckman, Trevor Simard, Marino Labinaz, Babak Nazer, Mark Wiley, Bhanu Gupta, Andrew Sauer, Hirak Shah, Paul Sorajja, Andres M Pineda, Emil Missov, Ehtisham Mahmud, Rami Kahwash, Scott Lilly, Azeem Latib, Sandhya Murthy, Neil Fam, Santiago Garcia, Eugene S Chung, Liviu Klein, Richard Cheng, Brian A Houston, Nicholas S Amoroso, Lee Chang, Sameer Gafoor, Sunit-Preet Chaudhry, James Hermiller, Jonathan G Schwartz, Lillian Aldaia, Konstantinos Koulogiannis, William A Gray, and Firas Zahr
Origin of biogeographically distinct ecotypes during laboratory evolution., Jacob J Valenzuela, Selva Rupa Christinal Immanuel, James Wilson, Serdar Turkarslan, Maryann Ruiz, Sean M Gibbons, Kristopher A Hunt, Nejc Stopnisek, Manfred Auer, Marcin Zemla, David A Stahl, and Nitin Baliga
Prognostic Implications of Quantifying Vasoactive Medications in Cardiogenic Shock., Saraschandra Vallabhajosyula, Anthony J Faugno, Borui Li, Kevin John, Qiuyue Kong, Shashank S Sinha, Jaime Hernandez-Montfort, Manreet K Kanwar, Jacob Abraham, Vanessa Blumer, Maryjane Farr, Justin Fried, Arthur R Garan, Shelley Hall, Gavin W Hickey, Rachna Kataria, J U Kim, Song Li, Claudius Mahr, Sandeep Nathan, Mohit Pahuja, Paavni Sangal, Andrew Schwartzman, VAN-Khue Ton, Oleg A Vishnevsky, Esther Vorovich, Karol D Walec, Peter Zazzali, Elric Zweck, Daniel Burkhoff, and Navin K Kapur
Combination therapy for kidney disease in people with diabetes mellitus., Daniël H van Raalte, Petter Bjornstad, David Z I Cherney, Ian H de Boer, Paola Fioretto, Daniel Gordin, Frederik Persson, Sylvia E Rosas, Peter Rossing, Jennifer A Schaub, Katherine Tuttle, Sushrut S Waikar, and Hiddo J L Heerspink
In Reply to Drs. Rousson, Hall, and Pasquier., Christopher Van Tilburg, Peter Paal, Giacomo Strapazzon, Colin K Grissom, Pascal Haegeli, Natalie Hölzl, Scott McIntosh, Martin Radwin, William Will R Smith, Stephanie Thomas, Bruce Tremper, David Weber, Albert R Wheeler, Ken Zafren, and Hermann Brugger
The Zea mays PeptideAtlas: A New Maize Community Resource, Klaas J van Wijk, Tami Leppert, Zhi Sun, Isabell Guzchenko, Erica Debley, Georgia Sauermann, Pratyush Routray, Luis Mendoza, Qi Sun, and Eric W Deutsch
Detection of the Arabidopsis Proteome and Its Post-translational Modifications and the Nature of the Unobserved (Dark) Proteome in PeptideAtlas, Klaas J van Wijk, Tami Leppert, Zhi Sun, Alyssa Kearly, Margaret Li, Luis Mendoza, Isabell Guzchenko, Erica Debley, Georgia Sauermann, Pratyush Routray, Sagunya Malhotra, Andrew Nelson, Qi Sun, and Eric W Deutsch
A real-world study of treatment sequences and second-line clinical outcomes in patients with HER2-positive metastatic breast cancer in US community practice., Della Varghese, Giovanna I Cruz, Colden Johanson, Liz Toland, Miguel Miranda, Eleanor C Faherty, David Harland, and Henry G Kaplan
A “SHIFT” in Behavioral Health Care: Putting Early Learnings into Action, Keri B Vartanian, Roxanne Marsillo, Benjamin Gronowski, Maggie Weller, Emily Root, Bradley Raburn, and Natalie Kenton
Evaluation of Piperacillin-Tazobactam Dosing and Clinical Outcomes in Obese Patients, Maria C. Vazquez, Shalyn Cox, and Larry J Pineda
Management of Neurologic Complications in Patients with Brain and Spine Tumors., Alipi V Bonm and Lynne P Taylor
Educational Needs and Attitudes of Clinical Nurses Providing End-of-Life Care to Patients with Terminal Illness, Kathryn Nicole Velichko and Annette Callis
An Educational Intervention Differentiating Between Pressure Injuries and End-of-Life Wounds, Alicia Perez Verela
